Privacy Policy


Introduction to our Privacy Policy


This Privacy Policy of Truffles, LLC and its affiliated entities (referred to as the "Company", "we", "our" or "us") outlines how your personally identifiable information and other personal data will be collected, used, and shared in connection with your access to and/or use of information about our Company or our services through the Truffles, LLC Web Site. This Privacy Policy describes what information we collect and how we use that information. If you have questions about this Privacy Policy, please in accordance with “Contacting Us”, below.

Your use of the Truffles, LLC Web Site constitutes your acceptance of and agreement to all of the terms and conditions in this Privacy Policy, our Terms of Service, and any community guidelines, policies, or rules now in force or enacted in the future, and any amendments and additions to these Terms as we may publish from time to time, as well as your compliance with all applicable laws. The Terms, and any community guidelines, policies, or rules now in force or upon their future enactment, are incorporated by reference into this Privacy Policy and together form and are hereinafter referred to collectively as this “Agreement”. Any terms not defined herein have the meanings ascribed to them in the Terms of Service. This Agreement governs the use of the Truffles, LLC Web Site, and you are giving the Company permission to use and store such information consistent with this Agreement.

Truffles, LLC provides the Truffles, LLC Web Site to allow an individual who is registered with Truffles, LLC (a "Customer") to request and schedule a session/appointment with us as a Recipient to receive minimally invasive medical aesthetic service, medical grade aesthetician services and other skincare and wellness services from Truffles, LLC. As used herein, the term “User” refers to any user of the Truffles, LLC Web Site. As used herein, the term "Account" may refer to the registered account of a Customer. A User who requests a Treatment through the Truffles, LLC Web Site may be referred to as the "Recipient" of that Treatment.

Information We Collect

Personal Information

As part of the operation of the Truffles, LLC Web Site and the provision of our Services to you, we will collect both personally identifying and non-personally identifying information from you (collectively, “Collected Information”).

By accessing our website(s) (including the Site), registering an Account with the Truffles, LLC Web Site, or using our Services, you agree that we can collect and use the information as described in this Privacy Policy. If you do not agree, you are neither permitted nor authorized to register or maintain an Account with Truffles, LLC, request or provide Treatments via the Truffles, LLC Web Site, access our website(s), or otherwise use or interact with our Services.

The types of Collected Information are described below:

As part of the operation of the Truffles, LLC Web Site and the provision of Services to you, we will collect, store, and use data that is (or may be combinable with other data in such a way as to be) personally identifiable to you (“Personal Information”), including but not limited to the following:

  • Contact Information – e.g. name, address, phone, email;
  • Demographic Information – e.g. sex, age;
  • Location Information – information about your geographic location or that of the device via which you access the Truffles, LLC Web Site;
  • Protected Health Information –individually identifiable health information, which may include demographic data, medical histories, test results;
  • Financial Information – information related to your banking or credit accounts;
  • Tracking Information – information related to the device you use to access the Truffles, LLC Web Site, e.g. cookies and related technologies; and
  • Other Information – miscellaneous information, e.g., your uploaded photograph, reviews you’ve submitted.
When you access our Site, register your Account and/or utilize our Services, we collect and store Personal Information. You also may choose to send the Company Personal Information in an email message containing information or inquiries about the Truffles, LLC Web Site. Many of the types of information described below can comprise Personal Information. We take the safety and integrity of your Personal Information very seriously.

Other than General Information, which may include Protected Health Information aggregated and/or anonymous information that is de-identified, we do not sell your information to third parties, and only share Personal Information under limited circumstances, as described. These limited circumstances in which Personal Information may be shared with third parties exclude text messaging originator opt-in data and consent – this information will not be shared with any third parties. We employ industry standard security measures as described below..

Protected Health Information

Our collection and use of your Personal Information, which we receive pursuant to this Agreement, is not governed by HIPAA. We will collect and use your Personal Information, including non-HIPAA covered Protected Health Information, consistent with the terms of this Agreement.

When you use the Service to upload, transmit, or receive Protected Health Information, you agree that, to the extent applicable, you shall comply with all applicable state and federal laws including, but not limited to, the Privacy Laws. You represent and warrant that you will, at all times, comply with all laws directly or indirectly applicable to you that may now or hereafter govern the gathering, use, transmission, processing, receipt, reporting, disclosure, maintenance, and storage of Protected Health Information. You agree that the Company, and all other persons or entities involved in the operation of the Service, have the right to monitor, retrieve, store, review, and use Protected Health Information, if applicable, in connection with the transmission of any Protected Health Information.

Tracking Information

“Cookies” are elements of data that a website can send to your browser and store on your computer. The Truffles, LLC Web Site and aspects thereof, and communications therewith, may use cookies, tracking pixels and related technologies. Cookies may also be used to track how you use the Truffles, LLC Web Site. Our cookies are not designed to collect Personal Information, but in some instances, may be combinable with other information to be personally identifiable. Our system may automatically gather information about the areas you visit on our Site or Truffles, LLC Web Site and about the links you may select from within our site to other areas of the Internet or elsewhere online. For example, cookies may be used by the Truffles, LLC Web Site to initiate shopping cart reminder messages for transactions that may take place through the Truffles, LLC communications (i.e., cookies are used to help keep track of items you put into your shopping cart, including when you have abandoned your cart and this information is used to determine when to send cart reminder messages via SMS).

We may use such information in the aggregate to understand how our users as a group use the services and resources provided on our sites. We may link such usage information to Collected Information in order to securely verify your identity, to personalize aspects of your experience on the Truffles, LLC Web Site, to better understand which information or services are of greater value to our Users, and to send follow-up communications regarding our products and services to website visitors. As with all other Personal Information, we do not sell Tracking Information to third parties.

You can choose whether to accept cookies by changing the settings of your browser. You can reset your browser to refuse all cookies, or allow your browser to show you when a cookie is being sent. You can also erase cookies already stored on your computer. If you choose not to accept these cookies or if you erase them, your experience on the Truffles, LLC Web Site, and other websites, may be diminished and some features may not work as intended.

Email and Text Messaging Communications

If you wish to unsubscribe from our email campaigns, please click on the Unsubscribe link at the bottom of any marketing email sent from us. If you opt out of our email marketing, we will still send you messages related to our transactions and relationship with you, such as appointment and/or order confirmations. If you wish to stop receiving text messages from us, reply STOP, QUIT, CANCEL, OPT-OUT, or UNSUBSCRIBE to any text message sent from us. For more information, see our Mobile Messaging Terms and Conditions.

Other Information

We may also collect other various data as part of the operation of the Truffles, LLC Web Site and the provision of our Services. We may also collect various other information, such as reviews, and your usage of promotional features. From time to time, Truffles, LLC may perform research (online and offline) via surveys. We may engage third party service providers to conduct surveys on our behalf. All survey responses are voluntary, and the information collected will be used for research and reporting purposes to help us better serve individuals by learning more about their needs and the quality of the products and services we provide. The survey responses may be utilized to determine the effectiveness of our Services, various types of communications, advertising campaigns and/or promotional activities. If an individual participates in a survey, the information given will be used along with that of other study participants. We may share anonymous individual and aggregate data for research and analysis purposes.

General Information

The Company may also collect, store, and utilize information related to the usage and operation of the Truffles, LLC Web Site and our Services that is aggregated, statistical, regional, anonymized, de-identified, or otherwise not identifiable to a natural person (collectively, "General Information"). The Company may publish or share, without restriction, General Information with third parties or the public. For example, the Company may compile and publish data related to numbers of registered Users, numbers of Treatments provided, Company revenue, average delivery time of Treatments, etc. We may also use General Information in order to help us improve our existing products and Services or develop new products and Services or we may sell or license anonymized or de-identified datasets derived from Collected Information for any lawful purpose, including but not limited to, supporting researchers in generating insights or to address hypotheses across a range of scientific, medical, clinical, or pharmaceutically-relevant questions. General Information is not Personal Information, and is expressly excluded from any restrictions in this Agreement upon Personal Information. As noted above, we provide and may sell General Information to third parties.

How Does the Company Use My Information?

We may use Collected Information to facilitate the use and operation of the Truffles, LLC Web Site and our Services, including the request and provision of Treatments, to service your Account, to communicate with you, to obtain your opinions on our Services, to send communications regarding our products and Services, to alert you to new features or information, and to improve the operation of the Truffles, LLC Web Site and our provision of Services to you. We may also collect and record information about usage of the Truffles, LLC Site in order to better serve our Users and enhance our products and Services.

Will the Company share my information?

The Company owns all the information collected from and about Users, as detailed in our Terms of Service. We do not rent, sell, or trade Personal Information to any third party. We may disclose or provide access to Personal Information to a third party in one of the following limited circumstances:

  • Where necessary for security purposes, to protect against fraud or unauthorized transactions, to resolve Customer disputes or inquiries, or to respond to requests from persons who are acting in a fiduciary or representative capacity for you, or who hold a legal or beneficial interest in your Account;
  • Where necessary for a third-party contractor, contracted by the Company, to perform services related to the Truffles, LLC Web Site;
  • To perform necessary identity and professional verification;
  • As permitted by applicable law, including in response to legal process or requests from government authorities;
  • In the event we go through a business transition, such as a merger, acquisition, divestiture, restructuring, reorganization, dissolution, bankruptcy, or sale of all or a portion of our assets, we may disclose your Personal Information to the party or parties of such transaction, Accounts and Collected Information may be disclosed to the party or parties involved in such transaction.

What Happens When I Close My Account?

If you close your Account with us, we will make reasonable efforts to delete your Account and Personal Information collected about you. Please note that our ability to delete data is subject to any data retention requirements imposed by law, regulation, or court order, and to the operational needs of the Truffles, LLC Web Site. Upon deletion from our active storage or database environment, information may persist in archival form. We will endeavor, as is practicable, to periodically purge from archival storage information that has been so deleted from our active storage or database environment, but make no guarantees as to the timing or our ability to do so.

We do not knowingly allow Users under the age of 18 to use the Truffles, LLC Web Site, and we do not knowingly collect information from any person under the age of 18. Use of the Truffles, LLC Web Site or our Services by anyone under the age of 18 is a violation of our Terms of Service and is expressly prohibited. If a person has nonetheless provided false information in order to register an Account, that person’s Account is subject to closure and any data associated therewith is subject to deletion.


The Company takes information security very seriously and has established physical and electronic security standards and procedures to protect against unauthorized access to Customer information. We use industry standard means such as physical, electronic and procedural safeguards, including, but not limited to data encryption and secure socket layer technology. We update and test our technology regularly to maintain and improve the protection of our Customers’ information. We restrict access of personal information to employees and service providers for legitimate business purposes to assist in providing services to you. Employees who violate our Privacy Policy are subject to disciplinary action.

Your Account is password protected. If you have reason to believe that your Account has been compromised or is no longer secure (e.g., because of activity you do not recognize, or because of a breach of your email, banking, credit, or any other financial or personal account), please immediately notify us of the problem by contacting us in accordance with “Contacting Us”, below.

Contacting Us

If you have any questions or concerns related to this Agreement, how to remove or modify your user information or related consents your Account, a Treatment, another User, or anything else regarding the Truffles, LLC or Services, please email us at or write to us at:

Truffles, LLC
874 West Lanier Avenue
Fayetteville, Georgia 30214



BOTOX® Cosmetic (onabotulinumtoxinA) is indicated in adult patients for the temporary improvement in the appearance of:
- moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity
- moderate to severe lateral canthal lines associated with orbicularis oculi activity
- moderate to severe forehead lines associated with frontalis activity



Postmarketing reports indicate that the effects of BOTOX® Cosmetic and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity but symptoms can also occur in adults treated for spasticity and other conditions, particularly in those patients who have an underlying condition that would predispose them to these symptoms. In unapproved uses, including spasticity in children, and in approved indications, cases of spread of effect have been reported at doses comparable to those used to treat cervical dystonia and spasticity and at lower doses.

BOTOX® Cosmetic is contraindicated in the presence of infection at the proposed injection site(s) and in individuals with known hypersensitivity to any botulinum toxin preparation or to any of the components in the formulation.

Lack of Interchangeability between Botulinum Toxin Products

The potency Units of BOTOX® Cosmetic are specific to the preparation and assay method utilized. They are not interchangeable with other preparations of botulinum toxin products and, therefore, units of biological activity of BOTOX® Cosmetic cannot be compared to nor converted into units of any other botulinum toxin products assessed with any other specific assay method.

Spread of Toxin Effect
Please refer to Boxed Warning for Distant Spread of Toxin Effect.
No definitive serious adverse event reports of distant spread of toxin effect associated with dermatologic use of BOTOX® Cosmetic at the labeled dose of 20 Units (for glabellar lines), 24 Units (for lateral canthal lines), 40 Units (for forehead lines with glabellar lines), 44 Units (for simultaneous treatment of lateral canthal lines and glabellar lines), and 64 Units (for simultaneous treatment of lateral canthal lines, glabellar lines, and forehead lines) have been reported.

Serious Adverse Reactions With Unapproved Use
Serious adverse reactions, including excessive weakness, dysphagia, and aspiration pneumonia, with some adverse reactions associated with fatal outcomes, have been reported in patients who received BOTOX® injections for unapproved uses. In these cases, the adverse reactions were not necessarily related to distant spread of toxin, but may have resulted from the administration of BOTOX® to the site of injection and/or adjacent structures. In several of the cases, patients had pre-existing dysphagia or other significant disabilities. There is insufficient information to identify factors associated with an increased risk for adverse reactions associated with the unapproved uses of BOTOX®. The safety and effectiveness of BOTOX® for unapproved uses have not been established.

Hypersensitivity Reactions
Serious and/or immediate hypersensitivity reactions have been reported. These reactions include anaphylaxis, serum sickness, urticaria, soft-tissue edema, and dyspnea. If such reactions occur, further injection of BOTOX® Cosmetic should be discontinued and appropriate medical therapy immediately instituted. One fatal case of anaphylaxis has been reported in which lidocaine was used as the diluent and, consequently, the causal agent cannot be reliably determined.

Cardiovascular System
There have been reports following administration of BOTOX® of adverse events involving the cardiovascular system, including arrhythmia and myocardial infarction, some with fatal outcomes. Some of these patients had risk factors including pre-existing cardiovascular disease. Use caution when administering to patients with pre-existing cardiovascular disease.

Increased Risk of Clinically Significant Effects with Pre-existing Neuromuscular Disorders
Individuals with peripheral motor neuropathic diseases, amyotrophic lateral sclerosis, or neuromuscular junction disorders (eg, myasthenia gravis or Lambert-Eaton syndrome) should be monitored when given botulinum toxin. Patients with neuromuscular disorders may be at increased risk of clinically significant effects including generalized muscle weakness, diplopia, ptosis, dysphonia, dysarthria, severe dysphagia, and respiratory compromise from onabotulinumtoxinA (see Warnings and Precautions).

Dysphagia and Breathing Difficulties
Treatment with BOTOX® and other botulinum toxin products can result in swallowing or breathing difficulties. Patients with pre-existing swallowing or breathing difficulties may be more susceptible to these complications. In most cases, this is a consequence of weakening of muscles in the area of injection that are involved in breathing or oropharyngeal muscles that control swallowing or breathing (see Boxed Warning).

Pre-existing Conditions at the Injection Site
Caution should be used when BOTOX® Cosmetic treatment is used in the presence of inflammation at the proposed injection site(s) or when excessive weakness or atrophy is present in the target muscle(s).

Human Albumin and Transmission of Viral Diseases
This product contains albumin, a derivative of human blood. Based on effective donor screening and product manufacturing processes, it carries an extremely remote risk for transmission of viral diseases and variant Creutzfeldt-Jakob disease (vCJD). There is a theoretical risk for transmission of Creutzfeldt-Jakob disease (CJD), but if that risk actually exists, the risk of transmission would also be considered extremely remote. No cases of transmission of viral diseases, CJD or vCJD have ever been identified for licensed albumin or albumin contained in other licensed products.

The most frequently reported adverse reaction following injection of BOTOX® Cosmetic for glabellar lines was eyelid ptosis (3%).

The most frequently reported adverse reaction following injection of BOTOX® Cosmetic for lateral canthal lines was eyelid edema (1%).

The most frequently reported adverse reactions following injection of BOTOX® Cosmetic for forehead lines with glabellar lines were headache (9%), brow ptosis (2%) and eyelid ptosis (2%).

Co-administration of BOTOX® Cosmetic and aminoglycosides or other agents interfering with neuromuscular transmission (eg, curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated. Use of anticholinergic drugs after administration of BOTOX® Cosmetic may potentiate systemic anticholinergic effects.

The effect of administering different botulinum neurotoxin products at the same time or within several months of each other is unknown. Excessive neuromuscular weakness may be exacerbated by administration of another botulinum toxin prior to the resolution of the effects of a previously administered botulinum toxin.

Excessive weakness may also be exaggerated by administration of a muscle relaxant before or after administration of BOTOX® Cosmetic.

There are no studies or adequate data from postmarketing surveillance on the developmental risk associated with use of BOTOX® Cosmetic in pregnant women. There are no data on the presence of BOTOX® Cosmetic in human or animal milk, the effects on the breastfed child, or the effects on milk production.

Please see BOTOX® Cosmetic full BOTOXcosmetic" target="_blank">Prescribing Information including Boxed Warning and Medication Guide.

CoolSculpting® Treatment Important Information

The CoolSculpting® procedure is FDA-cleared for the treatment of visible fat bulges in the thigh, abdomen and flank, along with bra fat, back fat, underneath the buttocks (also known as banana roll), and upper arm in patients with a Body Mass Index (BMI) of ≤ 30 and in submental and submandibular areas in patients with a BMI of ≤ 46.2. It is also FDA-cleared to affect the appearance of lax tissue with submental area treatments.

Important Safety Information
CoolSculpting® is contraindicated in patients with cryoglobulinemia, cold agglutinin disease, or paroxysmal cold hemoglobinuria.

Ask your patient about any medical conditions including recent surgery, pre-existing hernia, and any known sensitivities or allergies.

During the procedure patients may experience sensations of pulling, tugging, mild pinching, intense cold, tingling, stinging, aching, and cramping at the treatment site. These sensations subside as the area becomes numb. Following the procedure, typical side effects include temporary redness, swelling, blanching, bruising, firmness, tingling, stinging, tenderness, cramping, aching, itching, or skin sensitivity, and sensation of fullness in the back of the throat after submental or submandibular area treatment.

Rare side effects may also occur. Paradoxical hyperplasia (visibly enlarged tissue volume in the treated area) may develop 2-5 months after treatment and requires surgical intervention for correction.

As with any medical procedure, a consultation should be done by a licensed healthcare professional to determine if the patient is a candidate for treatment. Consult the CoolSculpting® System User Manual for a complete list of Contraindications, Warnings, Precautions, and potential side effects. Treatment applications that deviate from the guidelines are not recommended.

JUVÉDERM® Collection of Fillers Important Information

JUVÉDERM VOLUMA® XC injectable gel is indicated for deep (subcutaneous and/or supraperiosteal) injection for cheek augmentation to correct age-related volume deficit in the mid-face in adults over the age of 21.

JUVÉDERM® Ultra XC and JUVÉDERM® Ultra Plus XC injectable gels are indicated for injection into the mid-to-deep dermis for correction of moderate to severe facial wrinkles and folds (such as nasolabial folds).

JUVÉDERM VOLLURE™ XC injectable gel is indicated for injection into the mid-to-deep dermis for correction of moderate to severe facial wrinkles and folds (such as nasolabial folds) in adults over the age of 21.

JUVÉDERM® Ultra XC injectable gel is indicated for injection into the lips and perioral area for lip augmentation in adults over the age of 21.

JUVÉDERM VOLBELLA® XC injectable gel is indicated for injection into the lips for lip augmentation and for correction of perioral rhytids in adults over the age of 21.


These products should not be used in patients who have severe allergies, marked by a history of anaphylaxis or history or presence of multiple severe allergies, and should not be used in patients with a history of allergies to Gram-positive bacterial proteins or lidocaine contained in these products.

  • Do not inject into blood vessels. Introduction of these products into the vasculature may lead to embolization, occlusion of the vessels, ischemia, or infarction. Take extra care when injecting soft-tissue fillers; for example, inject the product slowly and apply the least amount of pressure necessary. Rare, but serious, adverse events associated with the intravascular injection of soft-tissue fillers in the face have been reported and include temporary or permanent vision impairment, blindness, cerebral ischemia or cerebral hemorrhage leading to stroke, skin necrosis, and damage to underlying facial structures. Immediately stop the injection if a patient exhibits any of the following symptoms: changes in vision, signs of a stroke, blanching of the skin, unusual pain during or shortly after the procedure. Patients should receive prompt medical attention and, possibly, evaluation by an appropriate healthcare professional specialist should an intravascular injection occur
  • Product use at specific sites in which an active inflammatory process (skin eruptions such as cysts, pimples, rashes, or hives) or infection is present should be deferred until the underlying process has been controlled
  • In order to minimize the risk of potential complications, these products should only be used by healthcare professionals who have appropriate training, experience, and knowledge of facial anatomy
  • Healthcare professionals are encouraged to discuss the potential risks of soft-tissue injections with their patients prior to treatment and ensure that patients are aware of signs and symptoms of potential complications
  • The safety and effectiveness for the treatment of anatomic regions other than the mid-face with JUVÉDERM VOLUMA® XC; facial wrinkles and folds with JUVÉDERM® Ultra XC, JUVÉDERM® Ultra Plus XC, and JUVÉDERM VOLLURE™ XC; and the lips and perioral area with JUVÉDERM® Ultra XC and JUVÉDERM VOLBELLA® XC have not been established in controlled clinical studies
  • As with all transcutaneous procedures, dermal filler implantation carries a risk of infection. Follow standard precautions associated with injectable materials
  • The safety for use during pregnancy, in breastfeeding females, and in patients with known susceptibility to keloid formation, hypertrophic scarring, and pigmentation disorders has not been studied
  • The safety for use of JUVÉDERM VOLUMA® XC in patients under 35 or over 65 years, JUVÉDERM® Ultra XC and JUVÉDERM® Ultra Plus XC in patients under 18 years, and JUVÉDERM VOLLURE™ XC and JUVÉDERM VOLBELLA® XC in patients under 22 years has not been established
  • Use with caution in patients on immunosuppressive therapy
  • Patients who are using products that can prolong bleeding (such as aspirin, nonsteroidal anti-inflammatory drugs, and warfarin) may experience increased bruising or bleeding at treatment sites
  • If laser treatment, chemical peel, or any other procedure based on active dermal response is considered after treatment, or if these products are administered before the skin has healed completely, there is a possible risk of an inflammatory reaction at the treatment site
  • Patients who experience skin injury near the site of implantation may be at a higher risk for adverse events
  • The safety of JUVÉDERM VOLUMA® XC injectable gel for use in patients with very thin skin in the mid-face has not been established
  • Patients may experience late onset nodules with use of dermal fillers, including JUVÉDERM VOLUMA® XC
  • Patients may experience late onset adverse events with use of dermal fillers

The most commonly reported side effects for JUVÉDERM® injectable gels were injection-site redness, swelling, pain, tenderness, firmness, lumps/bumps, bruising, discoloration, and itching. For JUVÉDERM VOLBELLA® XC, dryness was also reported. For JUVÉDERM VOLUMA® XC, side effects were predominantly moderate in severity, with duration of 2 to 4 weeks; for JUVÉDERM® Ultra XC, JUVÉDERM® Ultra Plus XC, or JUVÉDERM VOLLURE™ XC, they were mostly mild or moderate in severity, with duration of 14 days or less; and for JUVÉDERM VOLBELLA® XC, they were predominantly mild or moderate, with duration of 30 days or less.

To report an adverse reaction with any product in the JUVÉDERM® Collection, please call Allergan at 1-800-433-8871. Please visit for more information.

Products in the JUVÉDERM® Collection are available by prescription only.

KYBELLA® (deoxycholic acid) injection 10 mg/mL Important Information

KYBELLA® (deoxycholic acid) injection is indicated for improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults.

The safe and effective use of KYBELLA® for the treatment of subcutaneous fat outside the submental region has not been established and is not recommended.


KYBELLA® is contraindicated in the presence of infection at the injection sites.

Marginal Mandibular Nerve Injury
Cases of marginal mandibular nerve injury, manifested as an asymmetric smile or facial muscle weakness, were reported in 4% of subjects in the clinical trials; all cases resolved spontaneously (range 1-298 days, median 44 days). KYBELLA® should not be injected into or in close proximity to the marginal mandibular branch of the facial nerve.

Dysphagia occurred in 2% of subjects in the clinical trials in the setting of administration-site reactions, eg, pain, swelling, and induration of the submental area; all cases of dysphagia resolved spontaneously (range 1-81 days, median 3 days). Avoid use of KYBELLA® in patients with current or prior history of dysphagia as treatment may exacerbate the condition.

Injection-Site Hematoma/Bruising
In clinical trials, 72% of subjects treated with KYBELLA® experienced hematoma/bruising. KYBELLA® should be used with caution in patients with bleeding abnormalities or who are currently being treated with antiplatelet or anticoagulant therapy as excessive bleeding or bruising in the treatment area may occur.

Risk of Injecting Into or in Proximity to Vulnerable Anatomic Structures
To avoid the potential of tissue damage, KYBELLA® should not be injected into or in close proximity (1 cm-1.5 cm) to salivary glands, lymph nodes, and muscles.

Injection Site Alopecia
Cases of injection site alopecia have been reported with administration of KYBELLA®. Onset and duration may vary among individuals and may persist. Consider withholding subsequent treatments until resolution.

Injection Site Ulceration and Necrosis
Injections that are too superficial into the dermis may result in skin ulceration and necrosis. Cases of injection site ulceration and necrosis have been reported with administration of KYBELLA®. Do not administer KYBELLA® into affected area until complete resolution.

The most commonly reported adverse reactions in the pivotal clinical trials were: injection site edema/swelling, hematoma/bruising, pain, numbness, erythema, and induration.

Please see KYBELLA® full Prescribing Information.

LATISSE® (bimatoprost ophthalmic solution) 0.03% Important Information


LATISSE® (bimatoprost ophthalmic solution) 0.03% is indicated to treat hypotrichosis of the eyelashes by increasing their growth, including length, thickness, and darkness.

Important Safety Information

Contraindications: LATISSE® is contraindicated in patients with hypersensitivity to bimatoprost or to any of the ingredients.

Warnings and Precautions: In patients using LUMIGAN® (bimatoprost ophthalmic solution) or other prostaglandin analogs for the treatment of elevated intraocular pressure (IOP), the concomitant use of LATISSE® may interfere with the desired reduction in IOP. Patients using prostaglandin analogs including LUMIGAN® for IOP reduction should only use LATISSE® after consulting with their physician and should be monitored for changes to their intraocular pressure.

Increased iris pigmentation has occurred when bimatoprost solution was administered. Patients should be advised about the potential for increased brown iris pigmentation, which is likely to be permanent.

Bimatoprost has been reported to cause pigment changes (darkening) to periorbital pigmented tissues and eyelashes. The pigmentation is expected to increase as long as bimatoprost is administered, but has been reported to be reversible upon discontinuation of bimatoprost in most patients.

There is the potential for hair growth to occur in areas where LATISSE® solution comes in repeated contact with skin surfaces. Apply LATISSE® only to the skin of the upper eyelid margin at the base of the eyelashes.

LATISSE® solution should be used with caution in patients with active intraocular inflammation (eg, uveitis) because the inflammation may be exacerbated. LATISSE® should be used with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema.

Adverse Reactions: The most frequently reported adverse events were eye pruritus, conjunctival hyperemia, skin hyperpigmentation, ocular irritation, dry eye symptoms, and periorbital erythema. These reactions occurred in less than 4% of patients.

Postmarketing Experience: The following adverse reactions have been identified during postapproval use of LATISSE®: dry skin of the eyelid and/or periocular area, eye swelling, eyelid edema, hypersensitivity (local allergic reactions), lacrimation increased, madarosis and trichorrhexis (temporary loss of a few eyelashes to loss of sections of eyelashes, and temporary eyelash breakage, respectively), periorbital and lid changes associated with a deepening of the eyelid sulcus, rash (including macular and erythematous), skin discoloration (periorbital), and vision blurred.

Please see LATISSE® full Prescribing Information.

REVOLVE™ Advanced Adipose System
Indications and Important Safety Information

The REVOLVE™ Advanced Adipose System (REVOLVE™ System) is used for aspiration, harvesting, filtering, and transferring of autologous adipose tissue for aesthetic body contouring. This system should be used with a legally marketed vacuum or aspirator apparatus as a source of suction. If harvested fat is to be re-implanted, the harvested fat is only to be used without any additional manipulation. REVOLVE™ System is intended for use in the following surgical specialties when the aspiration of soft tissue is desired: plastic and reconstructive surgery, gastrointestinal and affiliated organ surgery, urological surgery, general surgery, orthopedic surgery, gynecological surgery, thoracic surgery, and laparoscopic surgery.


Contraindications to autologous fat transfer include the presence of any disease processes that adversely affect wound healing, and poor overall health status of the individual.

REVOLVE™ System must be used within the same surgical procedure. Reuse of this device in the same patient in a subsequent surgical procedure, or for more than one patient, may result in infection and/or transmission of communicable diseases. Do not use the product if sterile packaging is damaged.

This device will not, in and of itself, produce significant weight reduction. This device should be used with extreme caution in patients with chronic medical conditions such as diabetes, heart, lung, or circulatory system disease or obesity. The volume of blood loss and endogenous body fluid loss may adversely affect intra and/or postoperative hemodynamic stability and patient safety. The capability of providing adequate, timely replacement is essential for patient safety.

REVOLVE™ System is designed to remove localized deposits of excess fat through small incision and subsequently transfer the tissue back to the patient. Use of this device is limited to those physicians who, by means of formal professional training or sanctioned continuing medical education (including supervised operative experience), have attained proficiency in suction lipoplasty and tissue transfer. Results of this procedure will vary depending upon patient age, surgical site, and experience of the physician. Results of this procedure may or may not be permanent. The amount of fat removed should be limited to that necessary to achieve a desired cosmetic effect. Filling the device with adipose tissue over the maximum fill volume line can lead to occlusion of the mesh resulting in mesh tear.

Some common adverse effects associated with autologous fat transfer are asymmetry, over- and/or under-correction of the treatment site, tissue lumps, bleeding, and scarring. Potential adverse effects associated with REVOLVE™ System include fat necrosis, cyst formation, infection, chronic foreign body response, allergic reaction, and inflammation.

REVOLVESystem is available by prescription only.

For more information, please see the Instructions for Use (IFU) and User Manual for REVOLVESystem.

To report an adverse reaction, please call Allergan at 1.800.367.5737.